Patents by Inventor Roland J. Billedeau

Roland J. Billedeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230002437
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: May 13, 2021
    Publication date: January 5, 2023
    Inventors: Roland J. Billedeau, Jim Li, Lijing Chen
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 11208414
    Abstract: The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: December 28, 2021
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 11174261
    Abstract: The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: November 16, 2021
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20210261573
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: January 20, 2021
    Publication date: August 26, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjaer PETERSEN
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 11034715
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 15, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Roland J. Billedeau, Jim Li, Lijing Chen
  • Compositions and methods for inhibiting arginase activity
    Patent number: 11021495
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20200339607
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: February 14, 2020
    Publication date: October 29, 2020
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Lene Raunkjær PETERSEN
  • Ectonucleotidase Inhibitors and Methods of Use Thereof
    Publication number: 20200223882
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 16, 2020
    Inventors: Roland J. Billedeau, Jim Li, Lijing Chen
  • PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20200181154
    Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 11, 2020
    Applicant: Genentech, Inc.
    Inventors: Roland J. BILLEDEAU, James J. CRAWFORD, Saul JAIME-FIGUEROA, Wendy LEE, Francisco Javier LOPEZ-TAPIA, Sung-Sau SO
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10597411
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: March 24, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • Ectonucleotidase Inhibitors and Methods of Use Thereof
    Publication number: 20200087310
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: September 27, 2019
    Publication date: March 19, 2020
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 10570167
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 25, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Roland J. Billedeau, Jim Li, Lijing Chen
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 10472364
    Abstract: The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: November 12, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20190330244
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 31, 2019
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjær PETERSEN
  • PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20190194209
    Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Applicant: Genentech, Inc.
    Inventors: Roland J. BILLEDEAU, James J. CRAWFORD, Saul JAIME-FIGUEROA, Wendy LEE, Francisco Javier LOPEZ-TAPIA, Sung-Sau SO
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10287303
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 14, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20180222926
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 9, 2018
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Jr, Lene Raunkjaer PETERSEN, Francesco PARLATI, Matthew I. GROSS
  • Ectonucleotidase Inhibitors and Methods of Use Thereof
    Publication number: 20180186827
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: December 21, 2017
    Publication date: July 5, 2018
    Inventors: Roland J. Billedeau, Jim Li, Lijing Chen
  • ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180072742
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: September 8, 2017
    Publication date: March 15, 2018
    Inventors: Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
  • PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20180057500
    Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 29, 2017
    Publication date: March 1, 2018
    Applicant: Genentech, Inc.
    Inventors: Roland J BILLEDEAU, James J. CRAWFORD, Saul JAIME-FIGUEROA, Wendy LEE, Francisco Javier LOPEZ-TAPIA, Sung-Sau SO